What are the survival rates following consolidation therapy for acute myeloid leukemia (AML)?

Updated: May 26, 2020
  • Author: Karen Seiter, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

A study by Li et al of consolidation therapy in 45 patients with t(8;21) AML found that relapse-free survival (RFS) and overall survival (OS) were significantly higher with four courses of fludarabine plus cytarabine, compared with four courses of high-dose cytarabine, especially in patients without c-kit mutations. At 36 months, RFS for patients without c-kit mutations was 100% in those who received fludarabine plus cytarabine, compared with 57.8% in those who received high-dose cytarabine (P = 0.005); OS was 100% and 51.4%, respectively (P = 0.004). [51]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!